MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Vidofludimus

CAS No. : 717824-30-1

MCE 国际站：Vidofludimus

产品活性：Vidofludimus 是二氢乳清酸脱氢酶 (DHODH) 的抑制剂，也是法尼醇 X 受体 (FXR) 的新型调节剂，具有口服活性。Vidofludimus 作为一种免疫调节剂，可用于研究自身免疫性疾病，如炎症性肠病 (IBD)。Vidofludimus 还可通过靶向 FXR 用于脂肪肝的研究。

研究领域：Metabolic Enzyme/Protease  |  Immunology/Inflammation

作用靶点：Dihydroorotate Dehydrogenase  |  Interleukin Related  |  FXR

In Vitro: Vidofludimus (0-1 µM) selectively activats FXR in a concentration dependent manner with an EC₅₀ value of about 450 nM in inducing the recruitment of various coactivator LXXLL motifs.
Vidofludimus (0-8 μM) blocks nuclear translocation of p65 by suppressing IKK-IκB-NF-κB pathway.
Vidofludimus has inhibitory activity for human DHODH with an IC₅₀ value of 160 nM.
Vidofludimus inhibits dihydro-orotate dehydrogenase and lymphocyte proliferation in vitro.
Vidofludimus inhibits interleukin (IL)-17 secretion in vitro independently of effects on lymphocyte proliferation.
Vidofludimus completely blocks IL-23 + IL-1β-stimulated secretion of IL-17 by colonic strips in ex vivo.

In Vivo: Vidofludimus (i.p.; once daily; for 14 days) exerts effects on dextran sodium sulfate (DSS) induced colitis in an FXR-dependent manner in vivo.
Vidofludimus (p.o; 60 mg/kg; for 6 days) effectively improves many parameters of TNBS-induced colitis in rats and has inhibitory effects on colonic STAT3 and IL-17.

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Immunology/Inflammation Compound Library  |  Metabolism/Protease Compound Library  |  Clinical Compound Library  |  Drug Repurposing Compound Library  |  Differentiation Inducing Compound Library  |  Ferroptosis Compound Library  |  Pyroptosis Compound Library  |  Orally Active Compound Library  |  Angiogenesis-Related Compound Library  |  Mitochondria-Targeted Compound Library  |  Rare Diseases Drug Library  |  Nuclear Receptor Compound Library  |  Non-steroidal Anti-Inflammatory Compound Library  |  RCGD423  |  Farudodstat  |  Vunakizumab  |  Tagraxofusp  |  Dupilumab  |  IL-17A modulator-2  |  Chenodeoxycholic acid-d₅  |  Daclizumab  |  PNRI-299  |  DHODH-IN-21  |  Izokibep  |  Ginsenoside F3  |  Broussonin E  |  Clerodendrin  |  Vudalimab  |  1,4-Dicaffeoylquinic acid  |  Cetrelimab  |  Hydrangenol  |  Mulberroside A  |  Oxelumab  |  XJ02862-S2  |  FXR antagonist 1  |  Sirukumab  |  Y13g  |  Hedragonic acid  |  Ginsenoside Rc  |  DHODH-IN-23  |  Sevelamer  |  BIRT 377  |  Ixekizumab

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。